centro médico de San José s http://www.totmataro.cat/comprar-kamagra.html Cuál es el mejor seguro de salud http://www.totmataro.cat/cialis-20mg-precio.html píldoras de la dieta libre de cafeína

Presentaciones |16TH ASEICA INTERNATIONAL CONGRESS 2018

| 26 noviembre, 2018

TUESDAY 6th NOVEMBER

08:00 – 10:35 STUDENT WORKSHOP: SKILLS IN INVESTIGATION

08:05 – 08:25 Bibliometrics and science: importance of indicators in the research career
Dra. Rut Lucas. Universitat de València
Presentación


08:25 – 08:45 What to do after the BSc?
Dr. Rafael Sirera. Universitat Politècnica de València
Presentación


08:45 – 09:05 What comes after the PhD?
Dra. Deborah Burks. Centro de Investigación Príncipe Felipe director, Valencia
Presentación


09:05 – 09:25 How to choose the right mentor
Dra. Alba Maiques. CERU representative, London – UK
Dr. Juan Rodríguez Vita. CERFA representative, Heideberg – Germany
Presentación


09:25 – 09:45 Spin off Nanoimmunotech: from research to the company
Dra. África González. President of the Spanish Society for Immunology
Presentación


09:45 – 10:05 Clinical trials in cancer
Dr. Vicente Guillem. Instituto Valenciano de Oncología – IVO, Valencia
Presentación


11:00 – 12:30 KEY SESSION: TUMOR HETEROGENEITY

11:00 – 11:20 Breast cancer heterogeneity
Dr. Emilio Alba. Hospital Regional Universitario de Málaga y Virgen de la Victoria, Málaga
Presentación


11:20 – 11:40 Metastasis-initiating cells within tumors
Dr. Roger Gomis. Instituto de Investigación Biomédica de Barcelona
Presentación


11:40 – 12:10 Plenary lecture: Cancer evolution
Dr. David Posada. Universidad de Vigo
Presentación


12:30 – 13:50 JOINT SYMPOSIUM ASEICA – SEI: PRECISION MEDICINE WHEN THERE IS NOT A DRUGGABLE TARGET: IMMUNONCOLOGY

12:30 – 12:50 Novel approaches for NK cell based cancer immunotherapy
Dr. Francisco Borrego. Biocruces Bizkaia, Bilbao
Presentación


12:50 – 13:10 Use of dendritic cells for anti-tumor therapy
Dra. Jolanda de Vries. Radboud University, Nijmegen – Netherlands
Presentación


13:10 – 13:30 TILs and its applicability in cancer
Dra. Alena Gros. Vall d’Hebron Institut d’Oncologia – VHIO, Barcelona
Presentación


17:15 – 18:15 JOINT SYMPOSIUM ASEICA – SEOM: MILESTONES OF THE TRANSLATIONAL RESEARCH IN ONCOLOGY IN 2018

17:15 – 17:35 From the clinician’s point of view
Dr. Juan Manuel Sepúlveda. Hospital Universitario 12 de Octubre, Madrid
Presentación


17:35 – 17:55 From the researcher’s point of view
Dr. Piero Crespo. Instituto de Biomedicina y Biotecnología de Cantabria – IBBTEC, Santander
Presentación


19:00 – 20:25 COOPERATION IN PUBLIC-PRIVATE INNOVATION: NEW TECHNOLOGIES

19:20 – 19:30 PITX2 DNA-methylation, a novel validated marker in high-risk breast cancer
Dr. Olaf G. Wilhelm. Therawis Pharma GmbH. Munich, Germany
Presentación


19:30 – 19:40 Clinical use of Guardant 360 in gastrointestinal tumors
Dra. Clara Montagut. Hospital del Mar, Barcelona
Presentación


19:40 – 19:50 Liquid biopsies as important tool for the implementation of precision oncology. The example of OncoBEAM EGFR mutation assessment in lung cancer
Dra. Silvia Calabuig-Fariñas. Fundación Investigación Hospital General Universitario de Valencia
Presentación


20:00 – 20:10 EPICUP, an example of cooperative innovation in PP
Dr. Sebastián Morán. Head Dx Development Ferrer
Presentación


Oral Communications

TUMOR BIOLOGY – PARANINFO

15:15 – 15:21 Detecting hot-activity of retrotransposons in human tumours using a novel targeted sequencing-based method
Dra. Mónica Martínez-Fernández. Centro de Investigación en Medicina Molecular y Enfermedades Crónicas-CiMUS – Universidad Santiago de Compostela-USC.
Presentación


15:21 – 15:27 The transcription factor FOSL1 exerts an indisputable role in KRAS-driven cholangiocarcinoma
Dr. Adrián Vallejo. Centro de Investigación Médica Aplicada-CIMA, Pamplona
Presentación


15:27 – 15:33 STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis
Dra. Neibla Priego. Centro Nacional de Investigaciones Oncológicas – CNIO, Madrid
Presentación


TUMOR TREATMENT – SALÓN DE ACTOS

15:48 – 15:54 Lung-tumorspheres as an effective in vitro and in vivo platform for screening anti-cancer stem cell drugs
Dr. Héctor Amado. Fundación para la investigación del Hospital General Universitario de Valencia
Presentación


15:54 – 16:00 Extensive molecular profiling of lung cancer using new genetic platforms: A single institution’s experience
Dra. Cristina Teixidó. Hospital Clinic Barcelona
Presentación


WEDNESDAY 7th NOVEMBER

09:30 – 10:30 JOINT SYMPOSIUM ASEICA – INTERNATIONAL SOCIETY OF LIQUID BIOPSY ELUCIDATING THE COMPLEXITY OF LIQUID BIOPSIES

09:30 – 09:50 Exosomes and liquid biopsy
Dr. Héctor Peinado. Centro Nacional de Investigaciones Oncológicas – CNIO, Madrid
Presentación


09:50 – 10:10 cfDNA in liquid biopsy
Dra. Ana Vivancos. Vall d’Hebron Institut d’Oncologia – VHIO, Barcelona
Presentación


11:30 – 12:30 EDUCATIONAL SYMPOSIUM, OPTIMIZING THE TREATMENT IN 2019: MECHANISMS OF RESISTANCE TO ONCOGENIC DRIVERS IN LUNG CANCER: FUTURE APPROACHES IN THE LANDSCAPE

11:30 – 11:50 Facing up novel resistances with irreversible EGFR- kinase inhibitors in lung cancer
Dra. Noemí Reguart. Hospital Clínic de Barcelona
Presentación


11:50 – 12:10 Is there an optimal sequencing approach to overcome resistances in ALK-driven NSCLC tumors?
Dra. Enriqueta Felip. Hospital Universitari Vall d’Hebron, Barcelona
Presentación


12:30 – 14:00 CIBERONC SESSION : CANCER BIOINFORMATICS AND OMICS: BEYOND CANCER GENOMES

12:30 – 12:45 Greetings
Dr. Joaquín Arribas. CIBERONC Scientific Director
Presentación


12:45 – 13:30 Harnessing Big Data to help cancer patients
Dr. Xosé M. Fernández, Director of Data, Institut Curie
Presentación


13:30 – 13:45 Cancer Bioinformatics and Omics CIBERONC Work Module
Dr. Víctor Quesada. CIBERONC Work Module Leader
Presentación


13:45 – 14:00 CANCERTOOL: exploration, visualization and representation of cancer datasets
Dra. Verónica Torrano. CIC bioGUNE
Presentación


15:30 – 16:30 EDUCATIONAL SYMPOSIUM, OPTIMIZING THE TREATMENT IN 2019: TMB. FRONTIERS IN IMMUNOTHERAPY

15:30 – 15:50 Influences of the neoantigenic load in the response to immunotherapy. Consequences for the development of new drugs.
Dr. Luis Paz-Ares. Hospital Universitario 12 de Octubre, Madrid
Presentación


16:30 – 18:20 KEY SESSION: NOT ALL ROADS LEAD TO ROME: ONCOGENIC SIGNALING BEYOND THE TUMOR CELL

17:10 – 17:30 Cancer stem cells as drug target
Dr. Guillem Argilés. Hospital Universitari Vall d’Hebron, Barcelona
Presentación


17:30 – 18:00 Plenary lecture: Targeting the tumour microenvironment to control cancer growth
Dra. Kairbaan Hodivala-Dilke. Barts Cancer Institute, London – UK
Presentación


18:30 – 20:00 ASEICA WOMEN SESSION

Inspirational Lecture: Yes, we can
Sra. Elisa Martin. Chief Technology Officer IBM Spain
Presentación

Oral Communications

TUMOR BIOLOGY & TUMOR TREATMENT – PARANINFO

08:39 – 08:45 Myc inhibition by an Omomyc-based therapy induces immune cell recruitment to the tumor site in a model of NSCLC
Dra. Sílvia Casacuberta. Peptomyc S.L. Barcelona
Presentación


08:45 – 08:51 Development of polymer-based combination therapeutics for the treatment of Castration-Resistant Prostate Cancer (CRPC)
Dra. Sonia Vicente-Ruiz. Centro de Investigación Príncipe Felipe, Valencia
Presentación


LIQUID BIOPSY AND BIOMARKERS & TUMOR MICROENVIRONMENT SALÓN DE ACTOS

08:00 – 08:06 Exosomal miRNA profile in NSCLC: differential cargo between 2D and 3D cultures
Dra. Elena Durendez-Saez. Fundación Investigación Hospital General Universitario de Valencia
Presentación


08:06 – 08:12 Analysis of salivary cytokines and chemokines in early and advanced stages of oral squamous cell carcinoma (OSCC)
Dra. Valentina Dikova. Universitat de València
Presentación


08:12 – 08:18 SPOP and FOXA1 alterations in prostate cancer. Relationship with ERG overexpression and grade group classification
Dra. Silvia Hernández-Llodrà. Universitat Pompeu Fabra, Barcelona
Presentación


THURSDAY 8th NOVEMBER

08:00 – 09:20 YOUNG SESSION CIBER-SEAP-SEBBM: NOVEL APPROACHES IN CANCER RESEARCH

08:20 – 08:40 Comparative pathology and molecular characterization of tumors
Dra. Mireia Castillo. Chamapalimaud foundation, Lisboa – Portugal
Presentación


09:20 – 10:50 PRESIDENTIAL SESSION

09:20 – 09:50 Plenary lecture: Pi3K from biology to cancer and back
Dr. Bart Vanhaesebroek. UCL Cancer Institute, London – UK
Presentación


13:15 – 14:15 EDUCATIONAL SYMPOSIUM, OPTIMIZING THE TREATMENT IN 2019: NEW TREATMENT OPTIONS IN CYCLIN INHIBITORS

13:15 – 13:35 Where are they now and where are they headed in the future
Dra. Eva Ciruelos, Hospital Universitario 12 de Octubre, Madrid
Presentación


13:35 – 13:55 The spinning of CDK4/6 inhibitors in Hormone-Positive Breast Cancer Care
Dra. Ana Lluch. Hospital Clínico Universitario de Valencia
Presentación


Category: Sin categoría

Comments are closed.

La web que está visitando utiliza cookies propias y de terceros para mejorar la navegación y obtener datos estadísticos. Si quiere más información acceda a nuestra política de cookies si sigue navegando significa que acepta nuestra política de cookies.

ACEPTAR
Aviso de cookies